复发性妊娠丢失:两次或三次妊娠丢失后的诊断检查?系统综述与荟萃分析
该系统综述与荟萃分析旨在评估两次与三次或以上妊娠丢失夫妇中复发性妊娠丢失(RPL)异常检测结果患病率的证据。检索OVID Medline和EMBASE至2019年3月,纳入21项研究,19项适合荟萃分析。结果显示,子宫异常和抗磷脂综合征的患病率在两组间可能无差异,但染色体异常、遗传性血栓形成倾向和甲状腺疾病差异不能排除。结果可能支持两次妊娠丢失后进行检查,但需强调预后价值研究迫切需求。
要点
- 两次与三次以上妊娠丢失夫妇的子宫异常和抗磷脂综合征患病率可能无差异。
- 染色体异常、遗传性血栓形成倾向和甲状腺疾病的差异不能排除。
- 结果可能支持两次妊娠丢失后开始检查,但需更多预后研究。
核心结论
- 两次与三次以上妊娠丢失夫妇的子宫异常和抗磷脂综合征患病率差异不太可能。
- 染色体异常、遗传性血栓形成倾向和甲状腺疾病的患病率差异不能排除。
- 结果可能支持两次妊娠丢失后进行检查,但需迫切研究检测结果的预后价值。
研究设计与样本
- 系统综述与荟萃分析,检索OVID Medline和EMBASE从建库至2019年3月。
- 共纳入21项研究,其中19项适合荟萃分析。
- 使用Newcastle-Ottawa量表评估研究质量。
主要发现
- 子宫异常(7项研究,OR 1.00,95%CI 0.79-1.27,I2=0%)低质量证据显示两次与三次以上妊娠丢失无差异。
- 抗磷脂综合征(3项研究,OR 1.04,95%CI 0.86-1.25,I2=0%)低质量证据显示无差异。
- 染色体异常(10项研究,OR 0.78,95%CI 0.55-1.10)差异证据不足。
- 遗传性血栓形成倾向(5项研究)和甲状腺疾病(2项研究,OR 0.52,95%CI 0.06-4.56)差异证据不足。
关键数值与推荐
- 子宫异常:OR 1.00(95%CI 0.79-1.27),I2=0%。
- 抗磷脂综合征:OR 1.04(95%CI 0.86-1.25),I2=0%。
- 染色体异常:OR 0.78(95%CI 0.55-1.10)。
- 甲状腺疾病:OR 0.52(95%CI 0.06-4.56)。
临床怎么用
- 对于两次妊娠丢失的夫妇,可考虑进行RPL相关检查。
- 子宫异常和抗磷脂综合征的检查在两次妊娠丢失后即可考虑。
- 多数异常检测结果缺乏循证治疗,需个体化咨询。
局限性
- 子宫异常和抗磷脂综合征的证据质量低。
- 染色体异常、遗传性血栓形成倾向和甲状腺疾病的研究不足。
- RPL人群中检测结果的预后价值研究迫切需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent pregnancy loss (RPL) occurs in 1-3% of all couples trying to conceive. No consensus exists regarding when to perform testing for risk factors in couples with RPL. Some guidelines recommend testing if a patient has had two pregnancy losses whereas others advise to test after three losses. OBJECTIVE AND RATIONALE: The aim of this systematic review was to evaluate the current evidence on the prevalence of abnormal test results for RPL amongst patients with two versus three or more pregnancy losses. We also aimed to contribute to the debate regarding whether the investigations for RPL should take place after two or three or more pregnancy losses. SEARCH METHODS: Relevant studies were identified by a systematic search in OVID Medline and EMBASE from inception to March 2019. A search for RPL was combined with a broad search for terms indicative of number of pregnancy losses, screening/testing for pregnancy loss or the prevalence of known risk factors. Meta-analyses were performed in case of adequate clinical and statistical homogeneity. The quality of the studies was assessed using the Newcastle-Ottawa scale. OUTCOMES: From a total of 1985 identified publications, 21 were included in this systematic review and 19 were suitable for meta-analyses. For uterine abnormalities (seven studies, odds ratio (OR) 1.00, 95% CI 0.79-1.27, I2 = 0%) and for antiphospholipid syndrome (three studies, OR 1.04, 95% CI 0.86-1.25, I2 = 0%) we found low quality evidence for a lack of a difference in prevalence of abnormal test results between couples with two versus three or more pregnancy losses. We found insufficient evidence of a difference in prevalence of abnormal test results between couples with two versus three or more pregnancy losses for chromosomal abnormalities (10 studies, OR 0.78, 95% CI 0.55-1.10), inherited thrombophilia (five studies) and thyroid disorders (two studies, OR 0.52, 95% CI: 0.06-4.56). WIDER IMPLICATIONS: A difference in prevalence in uterine abnormalities and antiphospholipid syndrome is unlikely in women with two versus three pregnancy losses. We cannot exclude a difference in prevalence of chromosomal abnormalities, inherited thrombophilia and thyroid disorders following testing after two versus three pregnancy losses. The results of this systematic review may support investigations after two pregnancy losses in couples with RPL, but it should be stressed that additional studies of the prognostic value of test results used in the RPL population are urgently needed. An evidenced-based treatment is not currently available in the majority of cases when abnormal test results are present.
引用
- van Dijk MM, Kolte AM, Limpens J, et al. Recurrent pregnancy loss: diagnostic workup after two or three pregnancy losses? A systematic review of the literature and meta-analysis. Hum Reprod Update. 2020. PMID: 32103270. doi:10.1093/humupd/dmz048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。